Engineered Immunoglobulin Structural Loops for Novel Antigen Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods struggle to engineer immunoglobulins with specific binding properties to new antigen sites without disrupting the protein's structure and function, particularly in modifying structural loops to bind to epitopes that unmodified immunoglobulins do not recognize.
Innovation Solution
A method involving nucleic acid modification of structural loop regions in immunoglobulins, followed by expression and testing for specific binding to selected antigens such as allergens, tumor-associated antigens, or viral antigens, using techniques like phage display and site-directed mutagenesis to introduce new antigen binding sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If structural loop regions of immunoglobulins are modified to bind to new epitopes, then antigen binding specificity is improved, but protein structure stability may deteriorate
Solution Approach 1:
The patent applies local quality by making targeted amino acid modifications specifically in structural loop regions (such as H-loop, L-loop, and other non-CDR loops) while keeping the rest of the immunoglobulin structure intact. This allows the introduction of new binding specificities in localized areas without disrupting the overall protein stability and folding architecture.
Solution Approach 2:
The invention segments the immunoglobulin structure into distinct functional regions: variable domains with CDRs for traditional antigen binding, and structural loop regions for engineered binding. By treating these regions separately and modifying only the structural loops, the patent enables independent optimization of binding specificity while preserving the stability provided by the core immunoglobulin framework.
2Adaptability or versatility
If amino acid modifications are introduced in structural loops, then new binding properties are achieved, but manufacturing complexity increases
Solution Approach 1:
The patent utilizes parameter changes by systematically varying amino acid sequences in structural loop regions through site-directed mutagenesis and phage display technology. By changing specific parameters (amino acid composition, loop length, sequence motifs) in these regions, the invention generates diverse binding specificities using established molecular biology techniques, thereby managing manufacturing complexity through methodical parameter optimization rather than complete redesign.
3Adaptability or versatility
If structural loops are engineered for new epitope binding, then diagnostic and therapeutic applications are enhanced, but difficulty in detecting and measuring binding increases
Solution Approach 1:
The patent employs phage display technology as an intermediary system to detect and measure binding properties of engineered immunoglobulins. The phage display platform allows high-throughput screening of modified immunoglobulins against target epitopes, providing a standardized and scalable method to assess binding specificity and affinity without requiring complex custom assays for each variant.
Data Source
AI summary
Libraries of immunoglobulins which each have one or more amino acid modifications in at least one structural loop region of such immunoglobulins, where the modified loop region specifically binds to an epitope of an antigen to which an unmodified immunoglobulin does not significantly bind.